XM does not provide services to residents of the United States of America.
C
C

Croda

News

Alfa Laval, Ferrari NV, Swedbank

EUROPE RESEARCH ROUNDUP-Alfa Laval, Ferrari NV, Swedbank July 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, Ferrari NV and Swedbank, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 390 from SEK 385 * Ferrari NV RACE.MI : HSBC raises target price to EUR 385 from EUR 368 * Harworth Group Plc HWG.L : Peel Hunt raises target price to 195p from 165p * Moonpig Group MOONM.L : HSBC raises
A
A
A
B
B
B
B
B
B
C
C
C
E
E
F
H
H
I
P
P
S
V
A
A
D
S
S

ASMI, EasyJet, Kooth

EUROPE RESEARCH ROUNDUP-ASMI, EasyJet, Kooth July 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ASMI, EasyJet and Kooth, on Wednesday. HIGHLIGHTS * ASMI ASMI.AS : Jefferies raises target price to EUR 880 from EUR 780 * B.P. Marsh & Partners Plc BPM.L : Jefferies raises target price to 625p from 560p * EasyJet EZJ.L : JP Morgan cuts target price to 640p from 670p * Kooth Plc KOO.L : Berenberg initiates coverage with buy rating;
3
A
A
A
A
B
B
C
C
C
D
D
E
E
E
F
K
A
H
A
A
D

GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo

BUZZ-GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo ** Goldman Sachs favours consumer ingredient and gasses cos over diversified chemicals and paint makers based on pricing power, as the European chemicals sector faces an uneven recovery ** GS notes Europe's STOXX chemicals sub-index .SX4P is up 13% from its October 2023 tr
A
B
C
C
G
L
S
U
A
A

UK Stocks-Factors to watch on July 1

UPDATE 1-UK Stocks-Factors to watch on July 1 Updates futures, adds items July 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Monday, with futures FFIc1 up 0.34%. * ASTRAZENECA: AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
A
C
A

UK's Croda International names Stephen Oxley as next CFO

UPDATE 1-UK's Croda International names Stephen Oxley as next CFO Adds details from Johnson Matthey in paragraph 3 and interim CFO details in paragraph 4 July 1 (Reuters) - Chemicals maker Croda International CRDA.L on Monday said Stephen Oxley will join the company as its next CFO. Oxley, who is currently CFO of speciality chemicals maker Johnson Matthey JMAT.L , will join Croda no later than April 1, 2025, the company said.
C
J

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.